PURPOSE: This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancer patients treated with low-dose cyclophosphamide and bevacizumab. EXPERIMENTAL DESIGN: Seventy recurrent/metastatic epithelial ovarian cancer patients were enrolled in a phase II clinical trial. Genomic DNA was available from 53 blood samples. Polymorphisms were analyzed using the PCR-RFLP protocol. A 5' end 33P gammaATP-labeled PCR protocol was used to analyze dinucleotide repeats. RESULTS: Patients genotyped A/A or A/T for the IL-8 T-251A gene polymorphism had a statistically significant lower response rate (19%; 0%) than those homozygous T/T (50%; P = 0.006, Fisher's exact test). Patients carrying a minimum one C allele (C/C; C/T) of the CXCR2 C+785T polymorphism showed a median progression-free survival (PFS) of 7.4 months compared with the PFS of 3.7 months for those homozygous T/T (P = 0.026, log-rank test). Patients with the VEGF C+936T polymorphism C/T genotype had a longer median PFS of 11.8 months, compared with those with the C/C and T/T genotype, which had median PFS of 5.5 months and 3.2 months, respectively (P = 0.061, log-rank test). Patients carrying both AM 3'end alleles < 14 CA repeats had the shortest median PFS of 3.4 months; patients with at least one allele > 14 repeats or both alleles > 14 repeats showed a median PFS of 6.4 months and 7.2 months, respectively (P = 0.008, log-rank test). CONCLUSION: Our data suggest that the IL-8 A-251T polymorphism may be a molecular predictor of response to bevacizumab-based chemotherapy. The CXCR2 C+785T, VEGF C+936T single nucleotide polymorphisms and the AM 3' dinucleotide repeat polymorphisms may be molecular markers for PFS in ovarian cancer patients.
PURPOSE: This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancerpatients treated with low-dose cyclophosphamide and bevacizumab. EXPERIMENTAL DESIGN: Seventy recurrent/metastatic epithelial ovarian cancerpatients were enrolled in a phase II clinical trial. Genomic DNA was available from 53 blood samples. Polymorphisms were analyzed using the PCR-RFLP protocol. A 5' end 33P gammaATP-labeled PCR protocol was used to analyze dinucleotide repeats. RESULTS:Patients genotyped A/A or A/T for the IL-8 T-251A gene polymorphism had a statistically significant lower response rate (19%; 0%) than those homozygous T/T (50%; P = 0.006, Fisher's exact test). Patients carrying a minimum one C allele (C/C; C/T) of the CXCR2C+785T polymorphism showed a median progression-free survival (PFS) of 7.4 months compared with the PFS of 3.7 months for those homozygous T/T (P = 0.026, log-rank test). Patients with the VEGFC+936T polymorphism C/T genotype had a longer median PFS of 11.8 months, compared with those with the C/C and T/T genotype, which had median PFS of 5.5 months and 3.2 months, respectively (P = 0.061, log-rank test). Patients carrying both AM 3'end alleles < 14 CA repeats had the shortest median PFS of 3.4 months; patients with at least one allele > 14 repeats or both alleles > 14 repeats showed a median PFS of 6.4 months and 7.2 months, respectively (P = 0.008, log-rank test). CONCLUSION: Our data suggest that the IL-8A-251T polymorphism may be a molecular predictor of response to bevacizumab-based chemotherapy. The CXCR2C+785T, VEGFC+936T single nucleotide polymorphisms and the AM 3' dinucleotide repeat polymorphisms may be molecular markers for PFS in ovarian cancerpatients.
Authors: Michael A Gordon; Ji Gil; Bo Lu; Wu Zhang; Dongyun Yang; Jim Yun; Sylke Schneider; Susan Groshen; Syma Iqbal; Oliver A Press; Katrin Rhodes; Heinz-Josef Lenz Journal: Pharmacogenomics Date: 2006-01 Impact factor: 2.533
Authors: Yusuke Mizukami; Won-Seok Jo; Eva-Maria Duerr; Manish Gala; Jingnan Li; Xiaobo Zhang; Michael A Zimmer; Othon Iliopoulos; Lawrence R Zukerberg; Yutaka Kohgo; Maureen P Lynch; Bo R Rueda; Daniel C Chung Journal: Nat Med Date: 2005-08-28 Impact factor: 53.440
Authors: Gil Mor; Irene Visintin; Yinglei Lai; Hongyu Zhao; Peter Schwartz; Thomas Rutherford; Luo Yue; Patricia Bray-Ward; David C Ward Journal: Proc Natl Acad Sci U S A Date: 2005-05-12 Impact factor: 11.205
Authors: Robert M Strieter; Marie D Burdick; Javier Mestas; Brigitte Gomperts; Michael P Keane; John A Belperio Journal: Eur J Cancer Date: 2006-02-28 Impact factor: 9.162
Authors: Yan Ning; Philipp C Manegold; Young Kwon Hong; Wu Zhang; Alexandra Pohl; Georg Lurje; Thomas Winder; Dongyun Yang; Melissa J LaBonte; Peter M Wilson; Robert D Ladner; Heinz-Josef Lenz Journal: Int J Cancer Date: 2011-05-01 Impact factor: 7.396
Authors: Vincenzo Formica; Raffaele Palmirotta; Girolamo Del Monte; Annalisa Savonarola; Giorgia Ludovici; Maria Laura De Marchis; Italia Grenga; Michele Schirru; Fiorella Guadagni; Mario Roselli Journal: Int J Colorectal Dis Date: 2010-12-29 Impact factor: 2.571
Authors: Claudine Isaacs; Pia Herbolsheimer; Minetta C Liu; Mary Wilkinson; Yvonne Ottaviano; Gina G Chung; Robert Warren; Jennifer Eng-Wong; Philip Cohen; Karen L Smith; Karen Creswell; Antonella Novielli; Rebecca Slack Journal: Breast Cancer Res Treat Date: 2010-10-26 Impact factor: 4.872
Authors: Jane Yanagawa; Tonya C Walser; Li X Zhu; Longsheng Hong; Michael C Fishbein; Vei Mah; David Chia; Lee Goodglick; David A Elashoff; Jie Luo; Clara E Magyar; Mariam Dohadwala; Jay M Lee; Maie A St John; Robert M Strieter; Sherven Sharma; Steven M Dubinett Journal: Clin Cancer Res Date: 2009-11-03 Impact factor: 12.531
Authors: G Lurje; H Husain; D G Power; D Yang; S Groshen; A Pohl; W Zhang; Y Ning; P C Manegold; A El-Khoueiry; S Iqbal; L H Tang; M A Shah; H-J Lenz Journal: Ann Oncol Date: 2009-07-21 Impact factor: 32.976